Menopause, hormone replacement and gynaecological cancers

Menopause International

Volumn 16, Issue 2, 2010, Pages 89-93

  Hinds, Lynsey ^a   Price, John ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

gynaecological cancer; hormone replacement therapy; Menopause

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG SAFETY; ENDOMERIUM CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; GYNECOLOGIC CANCER; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; MENARCHE; MENOPAUSAL SYNDROME; MENOPAUSE; ONSET AGE; ORAL CONTRACEPTION; OVARY CANCER; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; UTERINE CERVIX CANCER; UTERUS TUMOR; VAGINA CANCER; VULVA CANCER; WART VIRUS; WOMEN'S HEALTH;

ADENOCARCINOMA; FEMALE; GENITAL NEOPLASMS, FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; NEOPLASMS, SQUAMOUS CELL; RISK FACTORS; SARCOMA, ENDOMETRIAL STROMAL;

EID: 77955892256     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2010.010018     Document Type: Review

References (23)

1. Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010; 65: 190–197
2. Gambacciani M, Monteleone P, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003; 17: 139–47
3. Burger CW, Van Leeuwen FE, Scheele F, Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999; 32: 69–76
4. WHI Writing Group. Estrogen-Alone Study. NHLBI website, 2004. See: www.nhlbi.nih.gov/whi/ (last accessed 19 July 2010)
5. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001; 54: 435–40
6. WHI writing group. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. JAMA 2002; 288: 321–33
7. 47th Study Group. Menopause and Hormone Replacement-Study Group Statement. London: RCOG Press, 2004
8. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systemic review and meta-analysis. Hum Reprod Update 2007; 1–11
9. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774–86
10. Cancer Research UK website. UK Cancer Statistics. See www.cancerresearchuk.org (last accessed 20 July 2010)
11. Suriano KA, Mchale M, McLaren CE,, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynaecol 2001; 97: 555–60
12. Creasman W, Henderson D, Hinshaw W, Clarke-Pearson D. Estrogen replacement in the patient treated for endometrial cancer. Obstetrician Gynaecol 1986; 67: 326–30
13. Lee R, Burke T, Park R. Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma. Gynaecol Oncol 1990; 36: 189–91
14. Chapman J, DISaia P, Osann K,, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynaecol 1996; 175: 1195–200
15. Barakat RR, Brundy BN, Spirtos NM,, et al. Randomised double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a gynaecologic oncology group study. J Clin Oncol 2006; 24: 587–92
16. International Menopause Society Expert Workshop. Hormone replacement therapy and cancer. Gynaecol Endocrinol 2001; 15: 453–65
17. Eeles RA, Tan S, Wiltshaw E,, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302: 259–62
18. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian cancer survivors: a randomised control trial. Cancer 1999; 86: 1013–18
19. Bebar S, Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 2000; 21: 192–196
20. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian cystadenocarcinoma treatment: the effect on survival. Menopause 2001; 8: 70–75
21. Mascarenhas C, Lambe M, Bellocco,, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006; 119: 2907–15
22. Luesley D, Acheson N. Gynaecological Oncology for the MRCOG and Beyond. London: RCOG Press, 2004
23. Ploch E. Hormone replacement therapy in patients after cervical cancer treatment. Gynaecol Oncol 1987; 26: 169–77